中国新药研发市场研究报告-Morgan Stanly 2012.11

yyphic

新药研发成为医疗行业的热点。
Contents
Summary of Key Findings from Our Analysis ............................................................................................................. 3
Summary of Important Stats from Our Analysis.......................................................................................................... 3
Investment Debates ....................................................................................................................................................... 4
Overview ......................................................................................................................................................................... 5
Key Findings from Our Analysis .................................................................................................................................. 9
(1) IND Stats .................................................................................................................................................................. 10
(2) Current Clinical Development Stats....................................................................................................................... 14
(3) NDA Stats ................................................................................................................................................................ 17
(4) Therapeutic Stats.................................................................................................................................................... 21
(5) Regulatory Approval Time Stats ............................................................................................................................ 26
(6) Regulatory Approval Rate Stats............................................................................................................................ 32
(7) China vs. US R&D and Regulatory Comparison................................................................................................... 35
Case Studies................................................................................................................................................................. 39
1) Beta Pharm ................................................................................................................................................................... 39
2) Hengrui Medicine .................................................................................................................................................. 40
Morgan Stanley’s Proprietary New Chinese Drug Database .................................................................................... 41
1) Pipeline summary of Our Coverage Companies.............................................................................................................................................. 40
2) Therapeutic Section-New Drug Database Sorted by Therapeutic Class and Indication.................................................................................... 57
3) Company Section-New Drug Database Sorted by Company Names................................................................................................................ 77

jackli_ib

太棒了，谢谢分享

不死鸟

谢谢分享，好东西

xinyang

不错，写招股书能提供下参考。